Gold Standard Diagnostics Launches Axis-Shield PLC’s New and Improved Anti-CCP2 Assay for Early and Accurate Diagnosis of Rheumatoid Arthritis

DAVIS, Calif.--(BUSINESS WIRE)--Gold Standard Diagnostics, Corp. (GSD) a leading supplier of products and services to the medical diagnostic industry today announced the launch of Axis-Shield’s new and improved Anti-CCP2 assay in the U.S. Market. Axis-Shield’s FDA cleared Anti-CCP2 assay is a new, highly sensitive and specific second generation peptide based test that enables early and accurate diagnosis of rheumatoid arthritis.